- Telehealth Visits
- Insurance plan information
Ruby Ghadially, MD
Dermatology- Telehealth Visits
- Insurance plan information
Ruby Ghadially, MD
Dermatology- Telehealth Visits
- Insurance plan information
On this page
Education & training
Board certification
- Dermatology, American Board of Dermatology
Fellowship
- Dermatology, VA Medical Center SF - GME
Residency
- Dermatology, University of Toronto GME
Internship
- Rotating, University of Toronto GME
Degree
- MBBCH, University of Sheffield
My expertise
Specialties
Locations
My research
Publications
Showing 1-6 of 31 reviews
- May 26, 20265 out of 5 Stars
Dr. Ghadially listened, communicated, and expressed genuine concern and support. I only wish my primary care physician was as engaged in resolving issues. I feel very fortunate to have her as my dermatologist. My experience with others in my area are very disappointing .
- May 5, 20265 out of 5 Stars
Appreciate her empathy about my concerns
- April 22, 20265 out of 5 Stars
Dr Ghadially is a very experienced and knowledgeable clinician. A real asset to the UCSF Derm
- April 17, 20265 out of 5 Stars
Dr. Ghadially has always been helpful
- January 11, 20265 out of 5 Stars
Dr. Ghadially is an outstanding dermatologist. She understands my skin issues perfectly, and takes excellent care of me!
- December 2, 20255 out of 5 Stars
Dr. Ghadially and I had a very positive and frank discussion about care, progress and my desire to work with her on my treatment. I was very pleased with her response and advice. She actively listened to me and gave good feedback.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.